Mandisa Singata-Madliki to Anti-HIV Agents
This is a "connection" page, showing publications Mandisa Singata-Madliki has written about Anti-HIV Agents.
Connection Strength
0,493
-
Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial. J Acquir Immune Defic Syndr. 2022 09 01; 91(1):26-30.
Score: 0,110
-
High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study. J Acquir Immune Defic Syndr. 2022 10 01; 91(2):130-137.
Score: 0,110
-
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life. Sci Rep. 2021 02 04; 11(1):3173.
Score: 0,100
-
Lopinavir-Ritonavir Impairs Adrenal Function in Infants. Clin Infect Dis. 2020 08 14; 71(4):1030-1039.
Score: 0,097
-
Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding. Antimicrob Agents Chemother. 2017 02; 61(2).
Score: 0,076